Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.58 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | ITK | Q08881 | 16/20 | 0.38 |
| ▸ | IL2 | P60568 | 4/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4946028 | 0.98 | AURKA (0.61) | AURKAAURKBCHEK1SRCCDK2 | |
| SCHEMBL4947802 | 0.91 | AURKA (0.47) | AURKAAURKBCHEK1SRCCDK2 | |
| SCHEMBL4948569 | 0.91 | AURKA (0.52) | AURKAAURKBCHEK1SRCCDK2 | |
| SCHEMBL4947379 | 0.88 | AURKA (0.55) | AURKAAURKBCHEK1SRCCDK2 | |
| SCHEMBL4948594 | 0.88 | AURKA (0.55) | AURKAAURKBCHEK1SRCCDK2 | |
| SCHEMBL4943746 | 0.87 | AURKA (0.55) | AURKAAURKBCHEK1SRCCDK2 | |
| SCHEMBL4944597 | 0.87 | AURKA (0.56) | AURKAAURKBCHEK1SRCCDK2 | |
| SCHEMBL4948528 | 0.85 | AURKA (0.44) | AURKAAURKBCHEK1SRCCDK2 | |
| SCHEMBL4950836 | 0.85 | AURKA (0.40) | AURKAAURKBCHEK1SRCCDK2 | |
| SCHEMBL4946094 | 0.84 | ITK (0.44) | AURKAAURKBCHEK1SRCCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885725-B1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2008-09-24 | — | — | EP | claimed |
| US-20060235013-A1 | Tricyclic azole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-19 | — | — | US | claimed |
| EP-1885725-B1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2008-09-24 | — | — | EP | disclosed |
| EP-1885725-A1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006108488-A1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-19 | — | — | WO | disclosed |
| US-20060235013-A1 | Tricyclic azole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235013-A1 | Tricyclic azole derivatives | CYP3A5, CYP3A43, CYP11B1 | AURKA 1207/4885AURKB 1249/4885CHEK1 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.